NCT06202066 2026-05-28Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine CarcinomasRoswell Park Cancer InstitutePhase 2 Recruiting60 enrolled